Low-Dose Abiraterone, a Rare European Commodity

Low-Dose Abiraterone, a Rare European Commodity

Bibliographic Details
Main Authors:	Niamh Peters, Mohammed Zeeshan Zameer, Seamus O'Reilly
Format:	Article
Language:	English
Published:	American Society of Clinical Oncology 2020-11-01
Series:	JCO Global Oncology
Online Access:	https://ascopubs.org/doi/10.1200/GO.20.00106

Similar Items

Potential Cost Savings With Low-Dose Abiraterone in the United States
by: Naveen Premnath, et al.
Published: (2020-11-01)

Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets
by: Amol Patel, et al.
Published: (2020-11-01)

Is flat dosing cost-effective? Re: ‘The same old story’: thoughts on authorised doses of anticancer drugs
by: Abdul R. Farooq, et al.
Published: (2020-12-01)

SPECTROPHOTOMETRIC AND LUMINESCENCE DETERMINATION OF ABIRATERONE ACETATE
by: I. I. Leonenko, et al.
Published: (2015-02-01)

A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer
by: Masaru Tani, et al.
Published: (2023-09-01)

Quadriplegia secondary to abiraterone-induced severe hypokalemia
by: Jignesh B Rajvanshi, et al.
Published: (2019-01-01)

Observational study on time on treatment with abiraterone and enzalutamide.
by: Giuseppe Fallara, et al.
Published: (2020-01-01)

Abiraterone Acetate Withdrawal Syndrome: Does It Exist
by: Hélène Gauthier, et al.
Published: (2012-07-01)

Editorial Comment: Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer
by: Felipe Lott
Published: (2020-11-01)

Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK – A16037)
by: Susana Banerjee, et al.
Published: (2020-12-01)

Design of Therapeutic Self-Assembled Monolayers of Thiolated Abiraterone
by: Elżbieta U. Stolarczyk, et al.
Published: (2018-12-01)

Design and Molecular Modeling of Abiraterone-Functionalized Gold Nanoparticles
by: Elżbieta U. Stolarczyk, et al.
Published: (2018-08-01)

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation
by: Timothy C. Wright, et al.
Published: (2021-07-01)

Fulvestrant-Big Mac Index: Defining Inequality in Oncology
by: David O'Reilly, et al.
Published: (2021-12-01)

Abiraterone acetate: a potential source of interference in testosterone assays.
by: Fairfax, B, et al.
Published: (2018)

Prescription pattern of abiraterone in Brazil - a survey of medical oncologists
by: João Pedro Homse-Netto, et al.
Published: (2023-08-01)

Optimisation of Air Source Heat Pumps in Residential Retrofits
by: Seamus Hoyne, et al.
Published: (2020-11-01)

Taking the Leap and Sustaining the Journey: Diversification on the Irish Family Farm
by: Aisling Moroney, et al.
Published: (2016-10-01)

Withdrawal syndrome and PSA flare in the management of mCRPC with abiraterone
by: Po Hui Chiang
Published: (2015-12-01)

Acute renal failure due to rhabdomyolysis in relation to abiraterone and rosuvastatin
by: Melissa Cintra, et al.
Published: (2023-05-01)

Abiraterone is associated with higher odds of cardiac complications compared to enzalutamide
by: E.B. Cone, et al.
Published: (2020-07-01)

Response of prostate cancer to addition of dutasteride after progression on abiraterone
by: Jian-Po Lian, et al.
Published: (2021-01-01)

Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy
by: Benjamin A. Gartrell, et al.
Published: (2015-08-01)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
by: Giorgia Gurioli, et al.
Published: (2020-09-01)

Do Commodities React More to Time-Varying Rare Disaster Risk? A Comparison of Commodity and Financial Assets
by: Peng Chen, et al.
Published: (2022-01-01)

Risk of hypertension in Cancer patients treated with Abiraterone: a meta-analysis
by: Xiaolei Zhu, et al.
Published: (2019-04-01)

Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis
by: Xiaolei Zhu, et al.
Published: (2019-06-01)

North-Europeans in Spain: 'Practices of community in the context of migration, mobility and transnationalism'
by: Erik Olsson, et al.
Published: (2017-09-01)

Fatal fulminant hepatitis in a patient taking abiraterone acetate: a case report
by: Dela Akpokavie, et al.
Published: (2023-06-01)

Effect of Dexamethasone on Abiraterone Pharmacokinetics in Mice: Determined by LC/MS Analysis
by: Subrata Deb, et al.
Published: (2023-03-01)

In Silico Taste–Toxicity Study of New Hypothetical Hetero-Abiraterone Derivatives
by: Kafa Khalaf
Published: (2022-10-01)

Targeted non AR mediated smart delivery of abiraterone to the prostate cancer.
by: Abu Baker, et al.
Published: (2022-01-01)

Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
by: Zobniw CM, et al.
Published: (2014-08-01)

Calibrating large-ensemble European climate projections using observational data
by: C. H. O'Reilly, et al.
Published: (2020-11-01)

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
by: Gustavo Werutsky, et al.
Published: (2019-05-01)

The influence of the Gulf Stream on wintertime European blocking
by: O'Reilly, CH, et al.
Published: (2015)

Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review
by: Yash B. Shah, et al.
Published: (2022-08-01)

To switch or not to switch? A real-life experience using dexamethasone in combination with abiraterone
by: Elisa Zanardi, et al.
Published: (2019-06-01)

Dose Finding and Food Effect Studies of a Novel Abiraterone Acetate Formulation for Oral Suspension in Comparison to a Reference Formulation in Healthy Male Subjects
by: Tamás Jordán, et al.
Published: (2021-12-01)

Pharmacokinetics and Bioequivalence of Abiraterone Acetate Tablets in Healthy Chinese Volunteers: An Open, Randomized, Single-Dose, Three-Period, Three-Sequence Crossover Study
by: Zhao-xin Wu, et al.
Published: (2023-04-01)